IRADIMED CORPORATION achieved record revenue of $22.7 million in Q4 2025, a 17% increase year-over-year, and reported GAAP diluted EPS of $0.50, up 25%. The company also increased its quarterly cash dividend to $0.20 per share, reflecting confidence in future business outlook.

IRadimed reported its seventeenth consecutive quarter of record revenue, reaching $21.2 million in Q3 2025. The company delivered GAAP EPS of $0.43 and non-GAAP EPS of $0.47, maintaining a strong 78% gross margin despite operational transitions. Full-year guidance was raised, reflecting robust demand and expectations for continued momentum.

Insperity posted a net loss for Q2 2025 due to rising healthcare and benefits costs, which outweighed a slight increase in revenue and paid worksite employees.

IRADIMED CORPORATION achieved record revenue of $19.5 million in the first quarter of 2025, an 11% increase year-over-year, alongside a 16% increase in GAAP diluted EPS to $0.37 and a 17% increase in non-GAAP diluted EPS to $0.42. The company also declared a quarterly cash dividend of $0.17 per common share.

IRadimed Corporation announced its Q4 and full year 2024 financial results, reporting record revenue of $19.4 million for the fourth quarter, an 11% increase compared to the same period in 2023. GAAP diluted EPS was $0.40 and non-GAAP diluted EPS was $0.44 for the fourth quarter. The company also increased its quarterly cash dividend to $0.17 per share.

IRADIMED CORPORATION announced record revenue of $18.3 million for Q3 2024, an 11% increase compared to Q3 2023. GAAP diluted EPS was reported as $0.40 and Non-GAAP diluted EPS as $0.43. The company is raising year-end guidance on GAAP diluted earnings per share to $1.49 to $1.52 and Non-GAAP diluted earnings per share to $1.64 to $1.67.

IRadimed Corporation reported record revenue of $17.9 million for Q2 2024, an 11.2% increase year-over-year. GAAP diluted EPS was $0.38, and non-GAAP diluted EPS was $0.42. Operating income increased by 13.4% to $5.6 million compared to the same period in 2023. The company declared a quarterly cash dividend of $0.15 per share.

IRadimed Corporation reported record revenue of $17.6 million for Q1 2024, a 13.7% increase compared to Q1 2023. GAAP diluted EPS was $0.32, and non-GAAP diluted EPS was $0.36. Operating income increased by 18.5% to $4.7 million.

IRADIMED CORPORATION announced its financial results for the fourth quarter ended December 31, 2023, reporting a 17.4% year-over-year revenue growth to $17.5 million. The company's net income was $4.5 million, or $0.36 per diluted share, and non-GAAP net income was $5.0 million, or $0.39 per diluted share.

IRADIMED CORPORATION announced record revenue of $16.5 million for the third quarter of 2023, representing a 23% year-over-year growth. The company's operating income increased by 43% compared to the same period in 2022, with GAAP diluted EPS of $0.40 and non-GAAP diluted EPS of $0.43.

IRadimed Corporation reported record revenue of $16.1 million for the second quarter of 2023, representing over 25% year-over-year growth. GAAP diluted EPS was $0.33, and non-GAAP diluted EPS was $0.36. The company also announced increased financial guidance for the full year 2023, expecting revenue between $64.5 million and $65.5 million.

IRadimed Corporation announced record revenue of $15.5 million for Q1 2023, representing over 25% year-over-year growth. The company's GAAP diluted EPS was $0.27, and non-GAAP diluted EPS was $0.30. Operating income increased by 30% to $4.0 million. The company also announced increased financial guidance for the full year 2023.

IRadimed Corporation announced its Q4 and full year 2022 financial results, reporting a revenue of $14.9 million for the quarter and $53.3 million for the year. The Board of Directors approved a special cash dividend of $1.05 per share. The company ended the year with $57.9 million in cash and cash equivalents and no debt.

IRadimed Corporation reported a revenue of $13.4 million, a 23% increase compared to Q3 2021. The company's operating income increased by 32% to $4.1 million, and GAAP diluted EPS grew by 35% to $0.27. Strong demand for IV pump and patient monitor product lines continued with bookings exceeding revenues, adding to the company's backlog.

IRadimed Corporation announced its Q2 2022 financial results, reporting record revenue of $12.7 million, a GAAP diluted EPS of $0.26, and a non-GAAP diluted EPS of $0.26. The company's orders exceeded shipments, resulting in a strong backlog entering the second half of the year.

iRadimed Corporation announced strong first-quarter results, with revenue increasing to $12.3 million compared to $9.2 million in the first quarter of 2021. Net income also rose to $2.5 million, or $0.20 per diluted share, compared to $1.4 million, or $0.11 per diluted share in the prior year. The company increased its full-year outlook, expecting revenue of $52.5 million to $53.2 million and non-GAAP earnings per share of $0.96 to $1.03.

iRadimed Corporation announced financial results for the three months and year ended December 31, 2021. Fourth quarter revenue grew nearly 39% over the fourth quarter last year and was supported by record bookings that grew over 48% from the fourth quarter last year.

iRadimed Corporation announced financial results for Q3 2021, with revenue of $10.9 million and net income of $2.6 million, or $0.20 per diluted share. Non-GAAP net income was $2.8 million, or $0.23 per diluted share.

IRadimed Corporation announced financial results for Q2 2021, with revenue of $9.8 million compared to $6.8 million for Q2 2020. Net income was $1.5 million, or $0.12 per diluted share, compared to a net loss of $(2.1) million, or $(0.17) per diluted share for Q2 2020. Non-GAAP net income was $1.7 million, or $0.14 per diluted share, compared to $0.6 million, or $0.05 per diluted share for Q2 2020.

IRadimed Corporation reported strong first-quarter results, with revenue exceeding internal expectations and a significant increase in income before taxes. The company's IV pump revenue grew by nearly 32% year-over-year, and backlog increased from already elevated levels.

IRadimed Corporation announced its Q4 2020 financial results, with revenue at $8.5 million and net income at $0.6 million, or $0.05 per diluted share. The company reported an 11% sequential increase in revenue compared to the third quarter. Bookings were close to the record set in Q4 of the previous year.

IRadimed Corporation announced its Q3 2020 financial results, reporting a revenue of $7.7 million compared to $10.0 million for Q3 2019. Net income was $1.1 million, or $0.09 per diluted share, compared to $2.5 million, or $0.20 per diluted share for Q3 2019.

iRadimed Corporation reported a decrease in revenue for the second quarter of 2020, with a net loss due to a one-time charge from the separation of its former CEO. However, the company saw encouraging signs from international demand and increased engagement with U.S. customers.

IRadimed reported a slight increase in revenue for the first quarter of 2020, with stable net income. The company's cash flow from operations increased, and it maintains a strong balance sheet despite the uncertainty created by COVID-19.

iRadimed Corporation announced financial results for Q4 2019, with revenue increasing over 30% compared to Q4 2018. The company reported net income of $3.2 million, or $0.26 per diluted share, compared to $1.7 million, or $0.14 per diluted share for the fourth quarter 2018.